company background image
NWRN logo

Newron Pharmaceuticals SWX:NWRN Stock Report

Last Price

CHF 8.49

Market Cap

CHF 165.2m

7D

3.5%

1Y

91.6%

Updated

24 Dec, 2024

Data

Company Financials +

Newron Pharmaceuticals S.p.A.

SWX:NWRN Stock Report

Market Cap: CHF 165.2m

My Notes

Capture your thoughts, links and company narrative

Newron Pharmaceuticals S.p.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Newron Pharmaceuticals
Historical stock prices
Current Share PriceCHF 8.49
52 Week HighCHF 11.45
52 Week LowCHF 4.37
Beta0.69
1 Month Change17.92%
3 Month Change13.20%
1 Year Change91.65%
3 Year Change430.63%
5 Year Change33.70%
Change since IPO-84.01%

Recent News & Updates

Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Sep 03
Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Recent updates

Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Sep 03
Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11
Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Nov 06
We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Apr 06
Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Apr 01
Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Feb 25
A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Shareholder Returns

NWRNCH PharmaceuticalsCH Market
7D3.5%-1.6%-1.8%
1Y91.6%4.0%1.5%

Return vs Industry: NWRN exceeded the Swiss Pharmaceuticals industry which returned 4% over the past year.

Return vs Market: NWRN exceeded the Swiss Market which returned 1.5% over the past year.

Price Volatility

Is NWRN's price volatile compared to industry and market?
NWRN volatility
NWRN Average Weekly Movement8.9%
Pharmaceuticals Industry Average Movement3.0%
Market Average Movement3.2%
10% most volatile stocks in CH Market7.4%
10% least volatile stocks in CH Market1.6%

Stable Share Price: NWRN's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: NWRN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
199922Stefan Weberwww.newron.com

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.

Newron Pharmaceuticals S.p.A. Fundamentals Summary

How do Newron Pharmaceuticals's earnings and revenue compare to its market cap?
NWRN fundamental statistics
Market capCHF 165.21m
Earnings (TTM)-CHF 17.63m
Revenue (TTM)CHF 6.52m

25.3x

P/S Ratio

-9.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NWRN income statement (TTM)
Revenue€6.97m
Cost of Revenue€0
Gross Profit€6.97m
Other Expenses€25.80m
Earnings-€18.83m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Apr 01, 2025

Earnings per share (EPS)-0.97
Gross Margin100.00%
Net Profit Margin-270.17%
Debt/Equity Ratio-157.4%

How did NWRN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 06:50
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Newron Pharmaceuticals S.p.A. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research